Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Eosinophilic Leukemia, Not Otherwise Specified: early-phase trial registry
1 of 2 indexed Chronic Eosinophilic Leukemia, Not Otherwise Specified trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Chronic Eosinophilic Leukemia, Not Otherwise Specified: 2 US clinical trials tracked, 1 recruiting.
Chronic Eosinophilic Leukemia, Not Otherwise Specified is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is William Shomali, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-eosinophilic-leukemia-not-otherwise-specified
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Chronic Eosinophilic Leukemia, Not Otherwise Specified lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Eosinophilic Leukemia, Not Otherwise Specified on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Eosinophilic Leukemia, Not Otherwise Specified is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
William Shomali
NCT03801434
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03862157
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Eosinophilic Leukemia, Not Otherwise Specified records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Eosinophilic Leukemia, Not Otherwise Specified trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Eosinophilic Leukemia, Not Otherwise Specified page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Chronic Eosinophilic Leukemia, Not Otherwise Specified trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- William Shomali sponsors the most Chronic Eosinophilic Leukemia, Not Otherwise Specified trials on record, review their full trial history before evaluating a specific study. See William Shomali's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Eosinophilic Leukemia, Not Otherwise Specified condition card totals 2 registered trials; most-linked intervention Pevonedistat; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.